A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma

Chao Lv¹, Yuanyuan Ma¹, Qin Feng², Fang Fang¹, Hua Bai³, Bingtian Zhao¹, Shi Yan¹, Nan Wu¹, Qingfeng Zheng¹, Shaolei Li¹, Jinfeng Chen¹, Jia Wang¹, Yuan Feng¹, Yuzhao Wang¹, Yuquan Pei¹, Jian Fang⁴ and Yue Yang¹*

Abstract

Background: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). This current pilot study assessed the feasibility of sequential induction therapy in patients with stage IIB to IIIA NSCLC adenocarcinoma.

Methods: Patients received gemcitabine 1,250 mg/m² on days 1 and 8 and cisplatin 75 mg/m² on day 1, followed by oral icotinib (125 mg, three times a day) on days 15 to 28. A repeat computed tomography (CT) scan evaluated the response to the induction treatment after two 4-week cycles and eligible patients underwent surgical resection. The primary objective was to assess the objective response rate (ORR), while EGFR and KRAS mutations and mRNA and protein expression levels of ERCC1 and RRM1 were analyzed in tumor tissues and blood samples.

Results: Eleven patients, most with stage IIIA disease, completed preoperative treatment. Five patients achieved partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (ORR=45%) and six patients underwent resection. Common toxicities included neutropenia, alanine transaminase (ALT) elevation, fatigue, dry skin, rash, nausea, alopecia and anorexia. No serious complications were recorded perioperatively. Three patients had exon 19 deletions and those with EGFR mutations were more likely to achieve a clinical response (P= 0.083). Furthermore, most cases who achieved a clinical response had low levels of ERCC1 expression and high levels of RRM1.

Conclusions: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies.

Keywords: Non-small-cell lung cancer, Sequential, Induction chemotherapy, EGFR mutation, Adenocarcinoma

Background

Stage IIB to IIIA non-small-cell lung cancer (NSCLC) has an unfavorable prognosis, with a low 5-year survival rate that ranges from 19% to 25% using clinical stage prediction, and a high recurrence rate despite aggressive surgical management [1,2]. Numerous trials have investigated the use of perioperative chemotherapy as a strategy to improve survival. A pooled analysis by the Lung Adjuvant Cisplatin Evaluation (LACE) Collaborative Group presented a 5-year absolute benefit of 5.4% using postoperative cisplatin-based chemotherapy, especially for stage II to III cases of NSCLC (hazard ratio (HR) = 0.83) [3]; while for the induction therapy, the Chemotherapy in Early Stages Trial (ChEST) yielded a significant improvement in terms of both disease-free survival (DFS; HR = 0.51) and overall survival (OS; HR = 0.42) of patients with clinical stage IIB to IIIA NSCLC using preoperative gemcitabine plus cisplatin [4].

Over the last decade, the development of targeted therapies have held great promise for the treatment of advanced NSCLC, and mutations of the epidermal growth factor receptor (EGFR) have been found in 15-20% of NSCLC patients [5]. EGFR mutations are predictive of response to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and have a favorable outcome in patients with NSCLC [6]. A study by Preusser et al. [7] evaluated the clinical benefit of EGFR-TKIs in patients with advanced NSCLC. EGFR mutations were associated with a higher response and a longer progression-free survival (PFS) duration in patients receiving EGFR-TKIs. Therefore, the use of EGFR-TKIs in patients with NSCLC has been recommended, and EGFR mutations have been identified as potential biomarkers for the selection of EGFR-TKIs in NSCLC [8].

Conclusion

This pilot study suggests that sequential gemcitabine/cisplatin and icotinib as induction therapy is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies.

Keywords: Non-small-cell lung cancer, Sequential, Induction chemotherapy, EGFR mutation, Adenocarcinoma
growth factor receptor (EGFR) gene were identified as a crucial factor that correlated with clinical responsiveness to tyrosine-kinase inhibitors (TKI) [5,6]. Gefitinib and erlotinib, which target the EGFR pathway, have been accepted as a superior initial treatment to chemotherapy for patients with EGFR mutations and advanced disease [7,8]. Icotinib, which is a potent and selective EGFR-TKI, provides a similar efficacy to gefitinib but with better tolerability for patients with NSCLC previously treated with one or two chemotherapy agents [9,10].

Although four randomized phase III trials that evaluated the efficacy of concurrent erlotinib or gefitinib administration with standard platinum-doublet chemotherapy failed to show evidence of improved survival [11-14], the phase II First-Line Asian Sequential Tarceva and Chemotherapy Trial (FAST-ACT) proved that the sequential administration of TKI following chemotherapy led to a significant improvement in progression-free survival (PFS; \( P = 0.0002 \)) and patients showed a trend toward a better tumor response rate (35.5% versus 24.4%; \( P = 0.12 \)) [15].

Based on the above findings, we designed and conducted this pilot study to assess the efficacy and tolerability of sequential gemcitabine/cisplatin and icotinib administration as an induction therapy for patients with stage IIB to IIIA NSCLC adenocarcinoma.

**Methods**

**Study design and eligibility criteria**

This was a single-arm study conducted in one center. The primary objective was to assess the objective response rate (ORR), while secondary objectives included safety and perioperative complications, as well as molecular markers for the prediction of tumor response. Patients with histologically confirmed NSCLC adenocarcinoma at stage IIB or IIIA were eligible for enrollment in this study. Other criteria included: age between >18 and <75 years old, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and ad

- Patients with histologically confirmed NSCLC adenocarcinoma at stage IIB or IIIA were eligible for enrollment in this study. Other criteria included: age between >18 and <75 years old, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and adequate hematological, hepatic and renal function (hemoglobin >10 g/dL, neutrophil count >2.0 × 10⁹/L, platelet count >100 × 10⁹/L, aspartate transaminase (AST; also known as serum glutamic oxaloacetic transaminase) <2.5 × the upper limit of normal; serum creatinine <1.25 × the upper limit of normal). Magnetic resonance imaging (MRI) studies of the brain, ultrasound examinations of the abdomen and supraclavicular lymph nodes, and bone scans were performed to exclude distant metastases. Positron emission tomography-computed tomography (PET-CT) was used as an option for staging. Cardiac and pulmonary function tests were also required before surgery was performed. Patients were excluded if they had received prior chemotherapy, radiotherapy or targeted therapy for any type of malignancy, and patients with interstitial lung disease were also excluded. Informed consent was obtained from patients who participated in the study and the study protocol was approved by the institutional ethics board.

**Study treatment protocol**

The chemotherapy regimen consisted of gemcitabine 1,250 mg/m² on days 1 and 8, followed by cisplatin 75 mg/m² on day 1. Subsequently, patients received continuous oral dosing with icotinib (125 mg, three times a day) on days 15 to 28 to complete the 4-week cycle. Toxicity was graded by the National Cancer Institute Common Toxicity Criteria, version 3.0. At the end of two cycles, a repeat computed tomography (CT) was performed to evaluate the response to the induction treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Subsequently, the resectability of each case was carefully assessed by experienced thoracic surgeons, and eligible patients proceeded directly to surgical resection within 2 weeks of the CT assessment. Perioperative complications were also recorded.

**Tumor tissue and plasma samples**

Tumor samples from pre-treatment biopsies and surgical specimens were fixed in buffered formalin and embedded in paraffin (FFPE) blocks. Sections from FFPE specimens were stained with hematoxylin and eosin, and the presence of tumor cells was confirmed by a pathologist. Blood samples were collected from each patient before and after the induction treatment, and DNA was extracted from plasma for further analysis.

**Detection of EGFR and KRAS mutations**

Genomic DNA was extracted from the FFPE samples using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). The DNA concentrations were measured by a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA). The 30 hotspot mutations within exons 18 to 21 of the EGFR gene were examined using the Human EGFR Mutation Qualitative Detection Kit (Beijing ACCB Biotech Ltd, Beijing, China). Hydrolysable fluorescent probes were specifically designed to detect different mutations (point mutations, insertions and deletions). The seven hotspot mutations in KRAS within codons 12 and 13 were detected by the Human KRAS Mutation Qualitative Detection Kit (Beijing ACCB Biotech Ltd, Beijing, China). This experiment was performed using the MX3000P PCR system (Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocol. The PCR conditions were as follows: initial denaturation at 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute.
Denaturing high-performance liquid chromatography (DHPLC) analysis
As described previously [16], EGFR (exon 19 and 21) mutations were detected in plasma using DHPLC Transgenomic Wave Nucleic Acid Fragment Analysis System (Transgenomic, Omaha, NE, USA).

Quantitative real-time PCR
Total RNA samples from the FFPE tissue sections were isolated by an RNeasy FFPE Kit (Qiagen) according to the manufacturer’s instructions. The concentrations of total RNAs were evaluated on the microspectrophotometer (OD260/230 ≥1.7; OD260/280 = 2.0 ± 0.2). The RNA samples were diluted to the working concentration of 20 ng/μL to 200 ng/μL. The expression levels of ERCC1 and RRM1 were examined using the Human ERCC1 and RRM1 Expression Relative Quantitative Detection Kits (Beijing ACCB Biotech Ltd). The reverse transcription was performed at 25°C for 10 minutes, followed by 37°C for 60 minutes. TaqMan probes were used to detect the expression levels of ERCCI and RRM1. ACTB (encoding β-actin) was used as the internal control. The PCR amplification was performed on the MX3000P (Stratagene) and the procedures were as follows: initial denaturation at 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. The relative amount of target genes was normalized to the internal reference gene (ACTB) using the 2−ΔCt method (ΔCt = Ct_target gene − Ct_ACTB). The relative expression level of ERCC1 and RRM1 was then categorized as high, moderate or low.

Immunohistochemistry
Briefly, 4-μm paraffin sections from paraffin blocks of clinical samples were prepared. After deparaffinization, the sections were treated with hydrogen peroxide (H2O2) for 5 minutes to block the endogenous peroxidase. These sections were stained with the mouse monoclonal anti-ERCC1 antibody (ZM-0138; ZSGB Biotech Ltd, Beijing, China) and anti-RRM1 antibody (60073-1-1g; Proteintech Group, Chicago, IL, USA). The tumor was considered to show positive expression when more than 10% of tumor cells were stained at any intensity.

Statistical analysis
The primary end point was the ORR according to the RECIST criteria. On the basis of a 45% response rate with a 95% confidence interval (CI) equal to the response rate plus or minus 30%, a sample size of 11 patients was estimated as necessary. The objective of statistical analysis was to detect the degree of correlation between the radiographic response to the induction treatment and the presence of an EGFR mutation. Statistical analysis was performed using patched SPSS 17.0 for Windows software (SPSS Inc, Chicago, IL, USA). Data were tested using Fisher’s exact test and the analysis results were considered significant at a level of P< 0.05.

Results
Patient characteristics
A total of 11 patients were enrolled in this study between August 2011 and April 2012 at a single department of Peking University Cancer Hospital (Beijing, China). The clinical characteristics of the patients are listed in Table 1. The patients included five males and six females, and most patients were identified as having stage IIIA disease before treatment; three patients had a bulky N2 metastasis. The majority of patients were diagnosed with adenocarcinoma (10 out of 11 patients), while one patient was diagnosed with adenosquamous carcinoma postoperatively.

Treatment delivered and toxicity
All 11 patients enrolled in the study completed two cycles of sequential treatment and six patients went on to undergo surgical resection. The median time from the start of treatment to surgery was 71 days, and the median time from the last dose to surgery was 14 days. The toxicities that occurred during the induction therapy are listed in Table 2. Most of the adverse events were grade 1 or 2, while only one case of grade 3 neutropenia was recorded. Common toxicities included neutropenia,
Alanine transaminase (ALT) elevation, fatigue, dry skin, rash, nausea, alopecia and anorexia. Neither dose reduction nor discontinuation was required in the induction cycles.

Treatment efficacy and surgical outcomes

After two cycles of sequential administration, 5 out of 11 patients achieved a partial response (PR) according to the RECIST criteria resulting in a response rate of 45%, but no complete response (CR) was observed. Among the six other patients, five patients had stable disease (SD) and one patient had progressive disease (PD) owing to the appearance of a supraclavicular lymph node metastasis. After the induction therapy was evaluated, all five patients with PR and the one patient with SD underwent surgery; while another three patients with SD and bulky mediastinal lymph node metastases received pemetrexed for chemotherapy owing to the unresectability of their disease. One patient with SD refused to undergo resection and opted for radiotherapy. The patients with PD also received radiotherapy.

For the six patients who received surgery, five patients underwent a complete lobectomy combined with systematic mediastinal lymph node dissection, and the other patient underwent a thoracotomy and exploration; pleural dissemination (M1a) was found and the operation was halted. Among the five lobectomies, two patients had a bronchoplasty and no angioplasty was performed. The postoperative pathological examinations confirmed that the diagnosis was consistent with the pre-treatment biopsy in all cases except one adenosquamous carcinoma, and no pathologic complete response (pCR) was noted. Two cases were down-staged by means of induction therapy, and another two patients who had been previously diagnosed stage IIB were later diagnosed to be mediastinal lymph node metastasis (stage IIIA). Postoperative complications included one case each of atelectasis, supraventricular arrhythmia and wound infection. No intraoperative hemorrhage or postoperative death was observed.

Molecular marker analyses

EGFR mutation analysis was performed on biopsy samples of nine patients before induction therapy, two of whom had exon 19 deletions. After surgery, specimens from six patients were available for analysis and three patients were confirmed to harbor exon 19 deletions. Neither exon 18, 20, 21, nor KRAS mutations, were detected in this cohort of patients. An increased trend toward achieving a clinical response was noted in patients with EGFR mutations, although the difference was not statistically significant \( (P=0.083) \). Plasma samples of 11 patients were collected before treatment in addition to the six surgical samples after induction therapy. However, no EGFR mutations were detected in the plasma samples collected according to the DHPLC method.

Expression analysis was only performed in resected tumors, and we observed that five out of six patients had high mRNA levels of RRM1 and low levels of ERCC1. All of these patients were scored as ERCC1-negative and three patients were RRM1-positive according to immunohistochemistry, respectively. All of the molecular data and treatment outcomes are listed in Table 3.

Discussion

To our knowledge, this is the first study to use sequential treatment as an induction therapy for NSCLC, and ORR was our primary outcome measure. The CHEST study achieved a response rate of 35.4% with gemcitabine and cisplatin as the induction regimen. Three clinical trials have evaluated the efficacy of preoperative EGFR-TKI, all of which enrolled patients with stage I to II NSCLC. The ORRs of these studies were unstable, ranging from 0% to 42% \( [17-19] \). In our study, we observed a response rate of 45% in patients with stage IIB to IIIA NSCLC, which was comparable to previous studies of induction therapy use for patients with early stage disease and for advanced disease in the FAST-ACT trial (ORR = 35.5%). In addition, the sequential administration of icotinib and chemotherapy

### Table 2 Toxicities related to the study treatment

| Toxicity         | Grade | Total | Grade | Total |
|------------------|-------|-------|-------|-------|
|                  | 1     | 2     | 3     | 4     |
| Hematological    |       |       |       |       |
| Leukopenia       | 3     | 2     | 0     | 0     | 5/11 (45%) |
| Neutropenia      | 2     | 2     | 1     | 0     | 5/11 (45%) |
| Anemia           | 2     | 0     | 0     | 0     | 2/11 (18%) |
| Thrombocytopenia | 2     | 1     | 0     | 0     | 3/11 (27%) |
| Biochemical      |       |       |       |       |
| Increased ALT    | 6     | 0     | 0     | 0     | 6/11 (55%) |
| Non-hematological|       |       |       |       |
| Rash             | 4     | 3     | 0     | 0     | 7/11 (64%) |
| Dry skin         | 4     | 2     | 0     | 0     | 6/11 (55%) |
| Pruritus         | 3     | 0     | 0     | 0     | 3/11 (27%) |
| Alopecia         | 6     | 2     | 0     | 0     | 8/11 (73%) |
| Mucositis        | 2     | 0     | 0     | 0     | 2/11 (18%) |
| Fatigue          | 5     | 2     | 0     | 0     | 7/11 (64%) |
| Anorexia         | 7     | 0     | 0     | 0     | 7/11 (64%) |
| Pyrexia          | 0     | 0     | 0     | 0     | 0/11 (0%) |
| Weight loss      | 0     | 0     | 0     | 0     | 0/11 (0%) |
| Nausea           | 9     | 0     | 0     | 0     | 9/11 (82%) |
| Vomiting         | 2     | 1     | 0     | 0     | 3/11 (27%) |
| Diarrhea         | 2     | 0     | 0     | 0     | 2/11 (18%) |
| Constipation     | 5     | 0     | 0     | 0     | 5/11 (45%) |

ALT, alanine transaminase.
EGFR ical response in each patient. However, an therapy plays the most important role in achieving clin-
make definite conclusions in this regard [10].

This result was consistent with the ICOGEN trial, which showed that icotinib caused less toxicity than gefitinib, although the number of cases in this study is too limited to show that icotinib caused less toxicity than gefitinib, although the number of cases in this study is too limited to make definite conclusions in this regard [10].

It is unclear whether the targeted therapy or chemotheraphy plays the most important role in achieving clinical response in each patient. However, an *EGFR* mutation is one of the most important factors to be considered. In the FAST-ACT study, six samples were available for the *EGFR* mutation analysis from patients who received sequential treatment, of which two patients had exon 19 deletions and achieved a PR. Among 11 pa-
tients, we observed that all three cases with an exon 19 deletion had a clinical response after induction therapy; for the seven patients with wild-type *EGFR*, only two met the criteria for a response. This result was consist-
ent with previous studies regarding gefitinib induction therapy [19]. Although only a non-significant trend was observed in favor of patients harboring *EGFR* mutations (*P* = 0.083), we believe that the difference would be significant if more patients were enrolled and unselected for other molecular markers.

It has been proven that *RRM1* and *ERCC1* mRNA levels and protein expression are predictive of response to gemicitabine and platinum-based chemotherapy [20,21]. In our study, most of the patients who had achieved a clinical response had low levels of *ERCC1* mRNA and high levels of *RRM1* mRNA, which was similar to the postoperative immunohistochemistry results. One possible explanation is that *RRM1* expression status might not be the crucial factor in this sequential treatment. In addition, although Bepler *et al.* concluded that post-chemotherapy gene expression levels were representative of pre-treatment levels, the analysis of 10 cases may not be sufficient. Furthermore, it has been noted that gene expression levels increase after chemo-

---

### Table 3 Treatment outcomes for patients associated with molecular marker status

| Patient | Gender | Smoking status | EGFR status | Biopsy | SS | Pre-Pl | Post-Pl | mRNA | IHC | mRNA | IHC | CR |
|---------|--------|----------------|-------------|--------|----|--------|---------|------|-----|------|-----|----|
| 1       | M      | Current        | Wild        | Ex19 Del | Wild | Wild   | Wild    | +    | (-) | +++  | (+) | PR |
| 2       | F      | Never          | Wild        | /       | Wild | /      | /       | /    | /   | /    | /   | SD |
| 3       | F      | Never          | Wild        | /       | Wild | /      | /       | /    | /   | /    | /   | SD |
| 4       | M      | Current        | /           | Wild    | Wild | Wild   | Wild    | +    | (-) | +++  | (-) | SD |
| 5       | F      | Never          | Wild        | Wild    | Wild | Wild   | Wild    | +    | (-) | +++  | (-) | PR |
| 6       | F      | Never          | Wild        | Wild    | Wild | Wild   | Wild    | +    | (-) | +++  | (+) | PR |
| 7       | F      | Never          | Ex19 Del    | Ex19 Del| Wild | Wild   | Wild    | +    | (-) | +++  | (+) | PD |
| 8       | M      | Current        | Wild        | /       | Wild | /      | /       | /    | /   | /    | /   | SD |
| 9       | M      | Current        | Ex19 Del    | Ex19 Del| Wild | Wild   | Wild    | +    | (-) | ++   | (-) | SD |
| 10      | M      | Current        | /           | /       | Wild | /      | /       | /    | /   | /    | /   | SD |
| 11      | M      | Former         | /           | /       | Wild | /      | /       | /    | /   | /    | /   | SD |

**CR:** clinical response; **EGFR:** epidermal growth factor receptor; **f:** female; **IHC:** immunohistochemistry; **M:** male; **PD:** progressive disease; **post-Pl:** post-treatment plasma; **PR:** partial response; **pre-Pl:** pre-treatment plasma; **SD:** stable disease; **SS:** surgical specimen.

was well tolerated with no serious adverse events recorded perioperatively. This was a better result than that of previous studies, especially with regards to rash and diarrhea. This result was consistent with the ICOGEN trial, which showed that icotinib caused less toxicity than gefitinib, although the number of cases in this study is too limited to make definite conclusions in this regard [10].

It is unclear whether the targeted therapy or chemotheraphy plays the most important role in achieving clinical response in each patient. However, an *EGFR* mutation is one of the most important factors to be considered. In the FAST-ACT study, six samples were available for the *EGFR* mutation analysis from patients who received sequential treatment, of which two patients had exon 19 deletions and achieved a PR. Among 11 patients, we observed that all three cases with an exon 19 deletion had a clinical response after induction therapy; for the seven patients with wild-type *EGFR*, only two met the criteria for a response. This result was consistent with previous studies regarding gefitinib induction therapy [19]. Although only a non-significant trend was observed in favor of patients harboring *EGFR* mutations (*P* = 0.083), we believe that the difference would be significant if more patients were enrolled and unselected for other molecular markers.

It has been proven that *RRM1* and *ERCC1* mRNA levels and protein expression are predictive of response to gemicitabine and platinum-based chemotherapy [20,21]. In our study, most of the patients who had achieved a clinical response had low levels of *ERCC1* mRNA and high levels of *RRM1* mRNA, which was similar to the postoperative immunohistochemistry results. One possible explanation is that *RRM1* expression status might not be the crucial factor in this sequential treatment. In addition, although Bepler *et al.* concluded that post-chemotherapy gene expression levels were representative of pre-treatment levels, the analysis of 10 cases may not be sufficient. Furthermore, it has been noted that gene expression levels increase after chemotherapy, which indicates that gemicitabine may alter *RRM1* mRNA levels [22]. To confirm this theory, a further study is needed to assess patients, with a radiographic response in particular.

Since *EGFR* mutation status has been considered to be a predictor of response to EGFR-TKI, the identification of patients with an *EGFR* mutation is important for the use of sequential induction therapy. Tumor tissue is the best choice for *EGFR* mutation analysis and these enable the microdissection of tumor cells. In our study, the postoperative samples of three patients were found to have exon 19 deletions, one of which could not be detected in the analysis of biopsy tissue preoperatively. Intratumor heterogeneity for *EGFR* mutation has been proven to exist by the analysis of different areas of a single NSCLC tumor [23], and further evidence of this heterogeneity stems from the predictive benefit of EGFR-TKI treatment from the relative abundance of *EGFR* mutations [24]. However, the difference in treatment efficacy between patients with and without heterogeneity appears to lie with PFS and OS, rather than the radiographic response, and the patient in our study also achieved a PR. When insufficient biopsy tissue or tumor cells are available for mutation analysis, the detection of mutations in plasma DNA might be an alternative. It has been reported that approximately 80% of mutations could be detected in both the plasma DNA and the corresponding tumor samples in patients with stage IIIIB to IV disease [16]. However, in our analysis, no *EGFR* mutation was detected in any plasma samples, either pre- or post-treatment. This negative result may have been
due to differences in the amount of circulating DNA derived from tumor tissues of patients with stage IIB to IIIA and advanced-stage NSCLC.

Conclusion
Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as the induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma. This regimen showed a promising ORR with no observed additional toxicity or postoperative complications, but this should be confirmed by studies with larger sample sizes. EGFR mutations appeared to be a predictor for response, which will be confirmed by further studies that may identify other molecular markers of clinical response as a result of sequential therapy.

Consent
Written informed consent was obtained from the patients for publication of this report and any accompanying images.

Abbreviations
ALT: alanine transaminase; AST: aspartate transaminase; ChESt: Chemotherapy in Early Stages Trial, CI: confidence interval; CR: complete response; CT: computerized tomography; DFS: disease-free survival; DHPLC: denaturing high-performance liquid chromatography; EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration; ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; ERCC1: excision repair cross-complementing rodent repair deficiency complementation group 1; FAST-ACT: First-Line Asian Sequential Tarceva and Chemotherapy Trial; FFPE: formalin and embedded in paraffin; HR: hazard ratio; IHC: immunohistochemistry; KRAS: v-N-ras2 Kirsten rat sarcoma viral oncogene homolog; LACE: Lung Adjuvant Ciplatin Evaluation Study; MRI: magnetic resonance imaging; NSCLC: non-small-cell lung cancer; ORR: objective response rate; OS: overall survival; PCR: polymerase chain reaction; PET: positron emission tomography-computed tomography; PFS: progression-free survival; PR: partial response; RECIST: Response Evaluation Criteria in Solid Tumors; RRM1: ribonucleoside-diphosphate reductase large subunit; SD: stable disease; TK1: tyrosine-kinase inhibitor.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
CI participated in the design of the study, performed the statistical analysis and drafted the manuscript. YMM, QF, FF, HB and BZ participated in study design, literature search and coordination. SL, JF, SF, JW, QZ, JC, JW, YF, YW and YP participated in the analysis of experimental results. YY conceived of the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Grant support
This research was supported with funds from Zhejiang Beta Pharma Inc.

Author details
1Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. 2Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. 3Department of Thoracic Medical Oncology I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China.

Received: 5 December 2012 Accepted: 8 April 2013 Published: 26 April 2013

References
1. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. JThoracOncol 2007, 2:706–714.
2. Lo Cicero J J: Surgical treatment of non-small-cell lung cancer. In General Thoracic Surgery. Volume 2. 7th edition. Edited by Shields TW, Lo Cicero J J, Reed CE, Feins RH. Lippincott Williams & Wilkins: Philadelphia, PA; 2009:1387–1426.
3. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Roselli R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding X, Waller D, Le Chevalier T, LACE Collaborative Group: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. JClinOncol 2008, 26:3552–3559.
4. Scagliotti GV, Pastirini U, Vansteenkiste JF, Spaggiari L, Facciolli F, Orlowski TM, Maiorino L, Hetzel M, Leschinger M, Visseren-Grut C, Torri V: Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. JClinOncol 2012, 30:172–178.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Halusa FG, Louis DN, Christiani DC, Setzen J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl J Med 2004, 350:2129–2139.
6. Paez JC, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fuji Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib/erlotinib. Science 2004, 304:1497–1500.
7. Mok TS, WuYL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margan Bo, Ichinose Y, Nishi Y, Ohe Y, Yang JJ, Chewswaylyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. NEngl J Med 2009, 361:947–957.
8. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xu Q, Ma J, Zhang L, You C: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 study. LancetOncol 2011, 12:735–742.
9. Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, Hu Y, He W, Wang Y, Wang Y: Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012, 76:177–182.
10. Sun YS, Zhang L, Liu X, Zhou C, Zhang L, Wang D, Li Q, Zhang S, Qin S, Hu C, Zhang Y, Chen J, Song Y, Feng JF, Cheng Y, Zhang H, Wu YL, Xu Y, Zhou J: A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J ClinOncol 2011, 29(suppl):abstr 7522.
11. Gazmeteier U, Pluzanska A, Szczena A, Kaukel E, Roube X, J De Rosa P, Tognoni GP, Balduini D, Maiorino S, Setacci L, Manikhas GM, Von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. JClinOncol 2007, 25:1545–1552.
12. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller FH, Von Pawel J, Pluzanska A, Gazmeteier U, Le Gros J, Ochs JS, Averbuch SD, Wolf MK, Krebs AD, Averbuch SD, Ochs JS,
Grous J, Fandi A, Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 2004, 22:785–794.

14. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892–5899.

15. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srinuninimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chu W, Lee JS: Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:5080–5087.

16. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27:2653–2659.

17. Haura EB, Sommers E, Song L, Chiappori A, Becker A: A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol 2010, 5:1806–1814.

18. Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boemer S, Sakurada A, Ludkovski O, Ma C, Squire J, Liu G, Shepherd FA, Tsuch MS, Leighl NB: Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 2009, 27:6229–6236.

19. Rizvi NA, Ruesch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG: Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 2011, 17:3500–3506.

20. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731–4737.

21. Reynolds C, Obasaju C, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O’Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Biomund J, Peng G, Monberg MJ, O’Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Biomund J, Peng G, Monberg MJ, Bepler G: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5806–5815.

22. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA: Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3:1112–1118.

23. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K: Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008, 99:929–935.

24. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yuan XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL: Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:3316–3321.